New insider activity at Cencora ( (COR) ) has taken place on December 22, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cencora has seen notable insider selling activity, with three top executives recently cashing out significant holdings. President & CEO Robert Mauch sold 5,096 shares of Cencora stock in a transaction valued at $1,750,221. Executive Vice President Elizabeth S. Campbell disposed of 3,351 shares for a total of $1,146,377. Additionally, Executive Vice President Silvana Battaglia sold 1,677 shares, generating proceeds of $578,565. These sales together highlight substantial profit-taking by Cencora’s leadership team.
Recent Updates on COR stock
In the last 24 hours, Cencora’s stock action has been driven mainly by guidance and analyst commentary rather than any single price shock. The company reaffirmed its fiscal 2026 revenue growth outlook of 5%–7%, signaling confidence in continued operational execution, but noted that its adjusted EPS for the current year is likely to land toward the lower end of its guidance range because it is pausing share repurchases to prioritize the planned acquisition of OneOncology—this trade-off between near-term EPS support and long-term strategic growth is a key factor behind analysts’ reassessments. Barclays initiated coverage with a positive stance on Cencora within a broadly neutral view of the U.S. healthcare technology and distribution space, citing a particularly favorable outlook on drug distributors relative to more mixed sentiment on dental and healthcare IT names, which underpins its constructive positioning on the stock. At the same time, newly disclosed risk-factor commentary emphasized Cencora’s exposure to disruptions from global events such as public health crises, natural disasters, and geopolitical tensions, reminding investors that supply-chain and operational volatility could materially pressure performance despite the company’s strong growth outlook and supportive Wall Street sentiment overall.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
Cencora’s strong financial performance and positive earnings call sentiment are major strengths, driving the score. However, high leverage, potential overvaluation, and technical indicators suggesting bearish momentum are notable risks.
To see Spark’s full report on COR stock, click here.
More about Cencora
YTD Price Performance: 52.91%
Average Trading Volume: 1,485,270
Technical Sentiment Signal: Buy
Current Market Cap: $66.14B